Objective—To evaluate effects of blood collection method and site on results of thromboelastography in healthy dogs.
Animals—8 clinically normal purpose-bred dogs.
Procedures—Blood was collected from the external jugular vein by syringe aspiration via direct venipuncture with a 20-gauge needle, through a central venous catheter, or into an evacuated tube with a 21-gauge winged needle catheter. Blood was collected from the lateral saphenous vein by syringe aspiration via direct venipuncture with a 20-gauge needle or into an evacuated tube with a 21-gauge winged needle catheter. Kaolin-activated thromboelastographic analyses were performed, and R (reaction time), K (clot formation time), α angle, maximal amplitude, and G (global clot strength) were analyzed.
Results—No significant differences were observed with regard to sampling site. Sample collection method had no effect on thromboelastographic results for saphenous vein samples. Blood samples collected from the jugular vein by syringe aspiration had a lower R and K and higher α angle than did blood samples collected from the jugular vein by evacuated tube collection. Significant differences were observed between blood samples collected from the jugular vein by syringe aspiration and samples collected from the saphenous vein by evacuated tube collection and between samples collected from the saphenous vein by evacuated tube collection and samples collected from the jugular vein through a central venous catheter.
Conclusions and Clinical Relevance—Different sampling methods resulted in small but significant differences in thromboelastographic values. Results justify the use of standardized techniques for research purposes, but all of these sampling methods were acceptable for 1-time clinical use.
Objective—To determine the correlation between activity as measured by an accelerometer and videographic measurements of movement and mobility in healthy dogs.
Animals—4 healthy dogs.
Procedures—After determination that accelerometers had good agreement, 5 identical accelerometers were used simultaneously to test their output at 8 locations (rotated among collar, vest, and forelimb stocking locations) on each dog. Movement and mobility for each dog were recorded continuously with a computerized videography system for 7-hour ses-sions on 4 consecutive days. Accelerometer values were combined into 439 fifteen-minute intervals and compared with 3 videographic measurements of movement and mobility (distance traveled, time spent walking > 20 cm/s, and time spent changing position by > 12% of 2-dimensional surface area during 1.5 seconds).
Results—96% of values compared between the most discordant pair of accelerometers were within 2 SDs of the mean value from all 5 accelerometers. All mounting locations provided acceptable correlation with videographic measurements of movement and mobility, and the ventral portion of the collar was determined to be the most convenient location.
Conclusions and Clinical Relevance—Use of an accelerometer was adequate for at-home activity monitoring, an important end point in clinical trials of treatment for chronic disease, and provided information about daily activity that is unattainable by other methods.
Objective—To evaluate the effect of acepromazine maleate administered IV on platelet function assessed in healthy dogs by use of a modified thromboelastography assay.
Animals—6 healthy adult mixed-breed dogs.
Procedures—Dogs received each of 3 treatments (saline [0.9% NaCl] solution [1 to 2 mL, IV] and acepromazine maleate [0.05 and 0.1 mg/kg, IV]) in a randomized crossover study with a minimum 3-day washout period between treatments. From each dog, blood samples were collected via jugular venipuncture immediately before and 30 and 240 minutes after administration of each treatment. A modified thromboelastography assay, consisting of citrated kaolin–activated (baseline assessment), reptilase-ADP–activated (ADP-activated), and reptilase-arachidonic acid (AA)–activated (AA-activated) thromboelastography, was performed for each sample. Platelet inhibition was evaluated by assessing the percentage change in maximum amplitude for ADP-activated or AA-activated samples, compared with baseline values. Percentage change in maximum amplitude was analyzed by use of Skillings-Mack tests with significance accepted at a family-wise error rate of P < 0.05 by use of Bonferroni corrections for multiple comparisons.
Results—No significant differences were found in the percentage change of maximum amplitude from baseline for ADP-activated or AA-activated samples among treatments at any time.
Conclusions and Clinical Relevance—Platelet function in dogs, as assessed by use of a modified thromboelastography assay, was not inhibited by acepromazine at doses of 0.05 or 0.1 mg/kg, IV. This was in contrast to previous reports in which it was suggested that acepromazine may alter platelet function via inhibition of ADP and AA.